Read by QxMD icon Read

non hodgkin lymphoma, diffuse large B cell, serum marker, prognostic

K Okuyucu, E Alagoz, S Ince, S Ozaydin, N Arslan
OBJECTIVE: Primary central nervous system (CNS) lymphoma is an aggressive and fatal extranodal non-Hodgkin lymphoma jailed in CNS at initial diagnosis. Its prognosis is poor and the disease has a fatal outcome when compared with systemic non-Hodgkin lymphoma. A few baseline risk stratification scoring systems have been suggested to estimate the prognosis mainly based on serum lactate dehydrogenase level,age, Karnofsky performance score, involvement of deep brain structures and cerebrospinal fluid protein concentration...
January 2018: Revista Española de Medicina Nuclear e Imagen Molecular
Aiko Kato, Yukihiro Imai, Kazunari Aoki, Sumie Tabata, Akiko Matsushita, Hisako Hashimoto, Takayuki Takahashi, Takayuki Ishikawa
Peripheral T cell lymphomas (PTCL) account for 10-15 % of non-Hodgkin's lymphomas and are associated with poor prognosis. Although many prognostic factors for PTCL have been proposed, the heterogeneity of PTCL seems to be an obstacle in the establishment of clinically useful prognostic system, such as the International Prognostic Index (IPI) in diffuse large B cell lymphoma. PTCL with nodal manifestation include the HTLV-I-negative histologic subtypes of PTCL not otherwise specified (PTCL-NOS), angioimmunoblastic T cell lymphoma (AITL), and anaplastic large cell lymphoma (ALCL)...
July 2014: Annals of Hematology
Gunter Assmann, Klara Shihadeh, Viola Poeschel, Niels Murawski, Jutta Conigliarou, Mei Fang Ong, Michael Pfreundschuh
BACKGROUND: Antibodies against citrullinated proteins (ACPA) have been recognised as the most specific serum marker for rheumatoid arthritis. However, serum autoantibodies such as anti-nuclear antibodies have also been detected in the sera of different lymphatic malignancies without accompanying rheumatologic disease. Therefore, we conducted a study to evaluate the prevalence of ACPA in diffuse large B-cell non-Hodgkin lymphoma (DLBCL). METHODS: Sera of 395 DLBCL patients and 258 age-matched healthy controls were investigated to evaluate the prevalence of ACPA and RF...
2014: PloS One
Junshik Hong, Hyun-Hwa Yoon, Hee Kyung Ahn, Sun Jin Sym, Jinny Park, Pil-Whan Park, Jeong Yeal Ahn, Sanghui Park, Eun Kyung Cho, Dong Bok Shin, Jae Hoon Lee
BACKGROUND/AIMS: Baseline serum lactate dehydrogenase (LDH) level is a well-known prognostic factor in patients with non-Hodgkin's lymphoma; however, its role beyond initial diagnosis has not yet been defined. METHODS: This study was conducted as a retrospective analysis of patients with diffuse large B cell lymphoma (DLBCL) treated with R-CHOP21, who had undergone regular checks for LDH during immunochemotherapy (n = 119) and during the posttreatment follow-up period after complete remission (CR; n = 100)...
2013: Acta Haematologica
Kun-Ming Chung, Sheng-Tsung Chang, Wen-Tsung Huang, Chin-Li Lu, Hung-Chang Wu, Wei-Shou Hwang, Kwang-Yu Chang, Shih-Sung Chuang
BACKGROUND/PURPOSE: The gastrointestinal tract is the most common site of primary extranodal non-Hodgkin lymphoma, and the prognostic factors of primary gastric diffuse large B-cell lymphoma (PG-DLBCL) differ in various studies. METHODS: We retrospectively searched for PG-DLBCL in a single institution, performed immunohistochemical analysis, classified tumor phenotype (Hans and Muris algorithms), reviewed medical records, and analyzed the clinical and immunophenotypic variables using Cox proportional hazard regression model...
July 2013: Journal of the Formosan Medical Association, Taiwan Yi Zhi
Qi-dong Ye, Ci Pan, Hui-liang Xue, Jing Chen, Min Zhou, Hua Jiang, Shu-hong Shen, Yan-jing Tang, Jian-min Wang
OBJECTIVE: To analyze outcomes and prognostic factors of children with B-cell non-Hodgkin lymphoma (B-NHL). METHODS: One hundred and four newly diagnosed B-NHL children were enrolled in protocol of B-NHL 2001. The statistics were performed by SPSS 13.0. RESULTS: Of 104 children (79 males, the median age of 7.1 years), 60, 32 and 4 patients were diagnosed with Burkitt lymphoma, diffuse large B-cell lymphoma and unclassifiable B-cell lymphoma, respectively...
May 2013: Zhonghua Xue Ye Xue za Zhi, Zhonghua Xueyexue Zazhi
Nobuhiko Nakamura, Naoe Goto, Hisashi Tsurumi, Masao Takemura, Nobuhiro Kanemura, Senji Kasahara, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Michio Sawada, Toshiki Yamada, Mitsuru Seishima, Tsuyoshi Takami, Hisataka Moriwaki
BACKGROUND: Serum soluble tumor necrosis factor receptor 2 (sTNFR2) concentration predicted the clinical outcome of patients with aggressive non-Hodgkin's lymphoma including diffuse large B-cell lymphoma (DLBCL) treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) in our previous study. However, after rituximab (R) was introduced in clinical practice, R-CHOP replaced CHOP as the standard therapy for DLBCL. PATIENTS AND METHODS: In this study, we re-evaluated the prognostic significance of serum sTNFR2 in 154 patients with DLBCL treated with R-CHOP...
October 2013: European Journal of Haematology
Demelza Hoogwerf, Jaap van Doorn, Eduard Maartense
Lactic acidosis is a rare complication of haematological malignancies with a poor prognostic outcome and unclear aetiology. Possible mechanisms include high rate of glycolysis by cancer cells, in part due to over-expression of hexokinase II. The insulin-like growth factor (IGF)-system has an important role in normal as well as tumour cell growth. We present a case of a 79-year-old man with a diffuse large B-cell lymphoma and lactic acidosis. Initially, the patient was successfully treated according to the R-CHOP scheme...
March 2013: Annals of Clinical Biochemistry
Fadia M Attia, Amany M Hassan, Nermine N El-Maraghy, Gehan H Ibrahium
INTRODUCTION: To date, little is known about blood immune marker changes that may be related to the development of Non Hodgkin Lymphoma (NHL) and treatment response with few serum biomarkers that could be useful in follow- up of the patients. OBJECTIVE: To quantify the expression of suppressor of cytokine signalling-3-(SOCS-3) gene at the mRNA level in the peripheral blood of patients with NHL and correlate with clinical pathological features and response to treatment...
0: Cancer Biomarkers: Section A of Disease Markers
Khalil M Charafeddine, Mark N Jabbour, Raneem H Kadi, Rose T Daher
Serum free light chain (sFLC) assays were shown to improve detection, management, and prognostication in plasma cell disorders. Recently, sFLC assays improved detection of M proteins when combined with standard methods of protein electrophoresis/immunofixation in patients with non-Hodgkin lymphoma/chronic lymphocytic leukemia (NHL/CLL). Incidence of abnormal sFLC ratio (sFLCr) varied from 0% to 36% and 29.7% to 59% in NHL and CLL, respectively. Increased sFLC levels or abnormal sFLCr predict shorter overall survival in early-stage CLL...
June 2012: American Journal of Clinical Pathology
Iman A Abd El Gawad, Hanan E Shafik
PURPOSE: CA 125 was evaluated in the sera of patients with aggressive NHL, together with LDH and β2m, in a trial to assess its value in the diagnosis and follow-up, and to compare it to some prognostic factors. SUBJECTS AND METHODS: The study included 78 newly diagnosed patients with diffuse large B cell non-Hodgkin's lymphoma (DLBCL), with age range 18-60 years, and a WHO performance status of 0, I or II, in addition to twenty apparently healthy controls. All patients received CHOP regimen for 6 cycles...
September 2009: Journal of the Egyptian National Cancer Institute
Rohan Khera, Snigdha Jain, Lalit Kumar, S Thulkar, M Vijayraghwan, R Dawar
Limited information is available from developing countries regarding clinico-pathological presentation of diffuse large B-cell lymphoma (DLBCL). We undertook a retrospective case record study to determine the clinico-laboratory characteristics, treatment outcomes, and prognostic factors for DLBCL and additionally analyzed percentage distribution and patient characteristics for other major subtypes of non-Hodgkin's lymphoma (NHL). DLBCL, constituting 59.3% of all NHL cases, was the predominant subtype. For DLBCL, males:females ratio was 2...
June 2010: Medical Oncology
Koen van Besien, Christian Gisselbrecht, Michael Pfreundschuh, Emanuele Zucca
The recurrence of non-Hodgkin lymphoma (NHL) in the central nervous system (CNS) is rapidly fatal in most cases. Highly aggressive lymphomas, such as lymphoblastic and Burkitt lymphomas, carry a high risk of CNS relapse. CNS relapse in intermediately aggressive subtypes, such as diffuse large B-cell lymphoma, is uncommon, but not rare. The risk of CNS relapse in indolent lymphomas is low. Prognostic markers of CNS relapse include elevated serum lactate dehydrogenase levels, the presence of B symptoms, and extranodal involvement at more than one site...
2008: Leukemia & Lymphoma
Laila A Eissa, Maha I Esmaeel
This study aimed to estimate the pretreatment serum levels of SVE-Cadherin, glycosaminoglycams (GAGs) and malondialdehyde (MDA) in order to evaluate their prognostic significance and their role in monitoring tumor response and overall-survival in Non Hodgkin lymphoma (DLCL) patients. Also the work aimed to investigate the relationship between levels of these biochemical markers with LDH level, ESR and tumor stage. For this purpose pretreatment serum levels of these biochemical markers were evaluated in 40 newly diagnosed patients with non-Hodgkin lymphoma (Diffuse large cell type) and studied in relation to expression in healthy control...
January 2008: Pakistan Journal of Pharmaceutical Sciences
Naoe Goto, Hisashi Tsurumi, Masao Takemura, Takeshi Hara, Michio Sawada, Senji Kasahara, Nobuhiro Kanemura, Toshiki Yamada, Masahito Shimizu, Takeshi Takahashi, Eiichi Tomita, Mitsuru Seishima, Tsuyoshi Takami, Hisataka Moriwaki
BACKGROUND: Recently investigators have worked to identify prognostic factors in non-Hodgkin's lymphoma (NHL) so an appropriate therapeutic plan can be put in action. The aim of the present study was to assess the prognostic significance of serum soluble tumor necrosis factor receptor (sTNF-R) 2 in aggressive NHL. METHODS: One hundred and ten consecutive patients with aggressive NHL who were previously untreated (diffuse large B-cell lymphoma; 94, peripheral T-cell lymphoma; 16) were prospectively enrolled in this study between 1997 and 2002...
September 2006: European Journal of Haematology
Hideko Goto, Hisashi Tsurumi, Masao Takemura, Yoriko Ino-Shimomura, Senji Kasahara, Michio Sawada, Toshiki Yamada, Takeshi Hara, Kenji Fukuno, Naoe Goto, Masataka Okuno, Tsuyoshi Takami, Mitsuru Seishima, Hisataka Moriwaki
PURPOSE: The aim of the present study was to assess the prognostic significance of serum soluble interleukin-2 receptor (sIL-2R) in aggressive non-Hodgkin's lymphoma (NHL). METHODS: One hundred and thirteen consecutive patients with previously untreated aggressive NHL (diffuse large B-cell lymphoma, 96; peripheral T-cell lymphoma, 17) prospectively participated in this study between 1995 and 2001. The patients were treated with 6-8 cycles of a CHOP or THP (pirarubicin)-COP regimen...
February 2005: Journal of Cancer Research and Clinical Oncology
Bungo Saito, Eisuke Shiozawa, Toshiko Yamochi-Onizuka, Daisuke Adachi, Tsuyoshi Nakamaki, Shigeru Tomoyasu, Mitsuhiro Omine, Toshiyuki Mitsuya, Masafumi Takimoto, Hidekazu Ota
Rituximab is widely used for the treatment of B-cell non-Hodgkin's lymphoma (NHL), and encouraging results have been obtained. However, some CD20-positive NHL show minimal response to rituximab, indicating that the treatment effect depends on the presence or absence of an unidentified factor. We analyzed the relationship between the effect of rituximab plus chemotherapy and expression of Ki-67, p53 and bcl-2 and several clinical variables in cases of B-NHL, particularly follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)...
September 2004: Pathology International
Amanda P Liggins, Barbara A Guinn, Chris S Hatton, Karen Pulford, Alison H Banham
Diffuse large B-cell lymphoma (DLBCL) accounts for 30-40% of all adult non-Hodgkin's lymphomas, yet the understanding of its underlying genetic abnormalities remains poor. Our present study used the serological analysis of recombinant cDNA expression libraries (SEREX) technique to identify DLBCL-associated antigens. SEREX screening of testis libraries has previously identified cancer-testis antigens (CTAs) that may act as disease-specific targets for immunotherapy. Screening a testis cDNA expression library with serum from a DLBCL patient identified a total of 94 positive clones, representing 28 distinct antigens...
July 1, 2004: International Journal of Cancer. Journal International du Cancer
Maurilio Ponzoni, Andrés J M Ferreri, Giancarlo Pruneri, Barbara Pozzi, Stefania Dell'Oro, Alessandra Pigni, Graziella Pinotti, Eugenio Villa, Massimo Freschi, Giuseppe Viale, Carlo Capella
bcl-6, CD10 and CD38 are useful markers for identifying 2 molecularly and prognostically distinct profiles of diffuse large B-cell lymphomas (LCLs), defined as germinal-center B-like and activated B-like. We investigated the prognostic role of bcl-6, CD10 and CD38 immunoreactivity in 102 gastrectomized patients with primary gastric lymphomas (PGLs). There were 41 low-grade marginal zone lymphomas of MALT-type (LGML) and 61 diffuse large B-cell lymphomas with (DLCLMLs; n = 31) or without (DLCLs; n = 30) an LGML component...
August 20, 2003: International Journal of Cancer. Journal International du Cancer
Petri Bono, Lasse Teerenhovi, Heikki Joensuu
BACKGROUND: Endostatin is a cleaved fragment of collagen Type XVIII and has antiangiogenic activity. The clinical significance of circulating, soluble endostatin (S-endostatin) is not known. METHODS: Pretreatment S-endostatin and serum vascular endothelial growth factor (S-VEGF) levels were measured in 143 patients with non-Hodgkin lymphoma (NHL) using competitive enzyme immunoassays and were compared with the levels from a control group (n = 24 participants). RESULTS: S-endostatin levels varied widely from 4...
June 1, 2003: Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"